1. ALLA AKTIER
  2. NYHETER
  3. IRLAB THERAPEUTICS

IRLAB Therapeutics

Nyheter IRLAB Therapeutics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

IRLAB participates at Aktiedagarna in Stockholm on June 9.

Gothenburg, Sweden, June 3, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces that CEO Kristina Torfgård and CFO Gustaf Albèrt will participate in Aktiespararna’s event Aktiedagarna in Stockholm.

IRLAB’s presentation will take place on Tuesday, June 9, 2026, at 16:25 and will be broadcast live via the following link: https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-68173. It will also be available afterwards on the company’s website, www.irlab.se.

Aktiedagarna is an investor event organized by Aktiespararna and will be held at Birger Jarl Conference in Stockholm on June 9–10. The event is a hybrid meeting that brings together investors, companies, and industry experts, and can be attended both in person and digitally.

For more information

Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: kristina.torfgard@irlab.se

About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB participates at Aktiedagarna in Stockholm on June 9.

Datum 2026-06-03, kl 07:00
Källa MFN
Bifogade filer
IRLAB participates at Aktiedagarna in Stockholm on June 9.